Literature DB >> 8901115

Effect of astilbin in tea processed from leaves of Engelhardtia chrysolepis on the serum and liver lipid concentrations and on the erythrocyte and liver antioxidative enzyme activities of rats.

K Igarashi1, Y Uchida, N Murakami, K Mizutani, H Masuda.   

Abstract

The effects of astilbin in Kohki tea, which is produced from the leaves of Engelhardtia chrysolepis Hance (Chinese name, huang-qui), and of an aglycone of astilbin, taxifolin, on the serum and liver lipid concentrations, and on the erythrocyte and liver antioxidative enzyme activities were determined with rats fed on a cholesterol-free diet. The total liver cholesterol concentration tended to be decreased by feeding with astilbin, and significantly decreased by feeding with taxifolin. The liver phospholipid concentration was decreased by feeding with both astilbin and taxifolin. In addition, astilbin and taxifolin lowered the serum and liver TBARS concentrations, but did not influence the serum and liver antioxidative enzyme activities, suggesting the possibility that these compounds acted to lower the TBARS concentration by their direct antioxidative action in vivo, almost without influencing the antioxidative enzyme activities.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8901115     DOI: 10.1271/bbb.60.513

Source DB:  PubMed          Journal:  Biosci Biotechnol Biochem        ISSN: 0916-8451            Impact factor:   2.043


  3 in total

1.  Taxifolin fibers as biomedical nanomaterial.

Authors:  Yu S Tarahovsky; Yu A Kim; G R Ivanitsky
Journal:  Dokl Biochem Biophys       Date:  2008 Sep-Oct       Impact factor: 0.788

Review 2.  Secondary Metabolites with Biomedical Applications from Plants of the Sarraceniaceae Family.

Authors:  Ileana Miclea
Journal:  Int J Mol Sci       Date:  2022-08-30       Impact factor: 6.208

3.  Screening the Best Compatibility of Selaginella moellendorffii Prescription on Hyperuricemia and Gouty Arthritis and Its Mechanism.

Authors:  Xue-Yan Zhang; Jing Cheng; Ping Zhao; Ke-Li Chen; Juan Li
Journal:  Evid Based Complement Alternat Med       Date:  2019-07-11       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.